Cellectis(CLLS) - 2024 Q3 - Quarterly Report

Financial Performance - Total revenues and other income for the nine-month period ended September 30, 2024, increased to $34,052,000, compared to$7,203,000 for the same period in 2023, representing a significant growth[7]. - The net loss attributable to shareholders for the nine-month period ended September 30, 2024, was $42,683,000, compared to a net loss of$66,648,000 for the same period in 2023, reflecting a reduction in losses[7]. - The basic net loss per share attributable to shareholders for the nine-month period ended September 30, 2024, was $(0.49), compared to$(1.09) for the same period in 2023[7]. - For the nine-month period ended September 30, 2023, net income was a loss of $66,648 thousand, compared to a loss of$42,683 thousand in 2024, reflecting a significant decline[8]. - The company reported a comprehensive income loss of $41.156 million for the nine-month period ended September 30, 2024[13]. - The net loss for the nine-month period ended September 30, 2024, was$42.683 million, compared to a net loss of $59.264 million for the same period in 2023[13]. Cash and Liquidity - Cash and cash equivalents as of September 30, 2024, amounted to$159,087,000, an increase from $136,708,000 as of December 31, 2023[6]. - Cash and cash equivalents at the end of the period for the nine-month period ended September 30, 2023, were$67,358 thousand, increasing to $159,087 thousand in 2024, indicating improved liquidity[11]. - Cash and cash equivalents stood at$159.1 million, with an additional deposit of $100.3 million, providing sufficient funds to support operations into 2027[20]. Research and Development - Research and development expenses for the nine-month period ended September 30, 2024, were$69,670,000, up from $62,690,000 in 2023, indicating an increase of approximately 11.5$69.7 million for the nine-month period ended September 30, 2024, up from $62.7 million in 2023, reflecting a rise of approximately 11.9$19,075 thousand, increasing to $23,829 thousand in 2024, indicating a rise in investment in innovation[9]. - The total research and development expenses for Q3 2024 were$23,829 million, reflecting a significant investment in innovation and product development[52]. Assets and Liabilities - Total assets increased to $395,876,000 as of September 30, 2024, compared to$334,270,000 as of December 31, 2023, showing a growth of approximately 18.4%[6]. - Total current liabilities increased to $165,650,000 as of September 30, 2024, from$155,144,000 as of December 31, 2023, representing a rise of about 6.5%[6]. - Non-current financial liabilities increased to $61,575,000 as of September 30, 2024, from$49,125,000 as of December 31, 2023, reflecting an increase of about 25.3%[6]. - Total financial liabilities increased from $135,151 thousand as of December 31, 2023 to$141,003 thousand as of September 30, 2024[91]. - Total deferred revenues and contract liabilities increased by $11.7 million to$122.0 million from $110.3 million as of December 31, 2023, primarily due to additional invoicing related to three Research Plans[108]. Shareholder Equity - Total shareholders' equity increased to$129,424,000 as of September 30, 2024, from $84,695,000 as of December 31, 2023, indicating a growth of approximately 52.7$129.424 million, an increase from $76.123 million as of September 30, 2023[13]. - The share capital increased to$5.9 million as of September 30, 2024, from $4.4 million as of January 1, 2024, following a capital increase involving the issuance of 28 million shares for$140.0 million[110]. - Cellectis' share capital increased to 100,093,873 shares as of September 30, 2024, up from 55,583,768 shares as of September 30, 2023[13]. Collaboration and Agreements - Cellectis entered into a Joint Research and Collaboration Agreement with AstraZeneca, aiming to develop up to 10 novel cell and gene therapy products[27]. - AstraZeneca made an initial equity investment of $80 million, acquiring approximately 22$25 million under the Joint Research Collaboration Agreement, with potential milestone payments ranging from $70 million to$220 million for each candidate product[28]. - The total upfront payments allocated to Research Plans amount to $109.1 million, including$25 million from the AZ JRCA and $48.4 million from the Subsequent Investment Agreement[36]. Financial Income and Expenses - The company reported a financial income of$29,727,000 for the nine-month period ended September 30, 2024, compared to $16,133,000 for the same period in 2023, marking an increase of approximately 84.5$29,727 million, up from $16,133 million in the same period of 2023, marking an increase of 84.5$23,085 million in the nine-month period ended September 30, 2023 to $24,049 million in 2024, a rise of 4.2$12,424 million in the nine-month period ended September 30, 2023, which decreased to $3,811 million in 2024, a decline of 69.4$1.8 million for the nine-month period ended September 30, 2024, compared to $2.0 million for the same period in 2023[115]. - The total number of shares outstanding increased to 100,093,873 as of September 30, 2024, reflecting the issuance of shares related to capital increases and employee stock options[110]. - The balance of non-employee warrants as of September 30, 2024, was 359,207, with a weighted-average exercise price of €26.69 and a remaining average useful life of 1.7 years[120].